Roca F J, Loomans H A, Wittman A T, Creighton C J, Hawkins S M
Department of Obstetrics and Gynecology, Indiana University School of Medicine, 550 N. University Blvd, UH2440, Indianapolis, IN 46202, USA.
Curr Mol Med. 2016;16(3):288-98. doi: 10.2174/1566524016666160225153844.
Our previous whole genome expression analysis of endometriomas suggested dysregulation of the ten-eleven translocation genes (TET1, TET2, and TET3), involved in converting 5- methylcytosine to 5-hydroxymethylcytosine (5-hmC). The objective of this study was to validate the expression of TET genes in ectopic and eutopic endometrium and in primary cultures of human endometrial stromal fibroblasts (HESF) during in vitro decidualization and to quantify 5-hmC levels in patients with endometriosis. Blood, eutopic endometrium, and endometriotic tissues were collected at time of gynecologic surgery. HESF cultures were created from eutopic endometrium of women without (HESF-CONTROL) and with endometriosis (HESF-ENDO) and underwent in vitro decidualization. Genomic DNA from blood and tissues underwent quantification of the absolute amount of 5-hmC using ELISA. The expression of TET1, TET2, and TET3 was decreased in endometriosis compared to non-endometriosis control eutopic endometrium. Surprisingly, the global amount of 5-hmC was higher in ectopic endometrium than control eutopic endometrium, while genomic DNA from blood of women with endometriosis contained statistically significantly less 5-hmC than women without endometriosis. Expression of TET1, TET2, and TET3 was decreased in non-decidualized HESFENDO. Upon in vitro decidualization, control HESF showed decreased expression of TET3, while decidualized HESF-ENDO showed no statistically significant change in expression of TET1, TET2, or TET3. These results indicate that the TET genes are downregulated in ectopic endometrium and in HESF-ENDO, and suggest for the first time that TET genes play a role in endometriosis. High global amounts of 5-hmC in endometriotic tissues suggest unique epigenetic regulation in these tissues.
我们之前对子宫内膜异位囊肿进行的全基因组表达分析表明,参与将5-甲基胞嘧啶转化为5-羟甲基胞嘧啶(5-hmC)的10-11易位基因(TET1、TET2和TET3)存在失调。本研究的目的是验证TET基因在体外蜕膜化过程中异位和在位子宫内膜以及人子宫内膜基质成纤维细胞(HESF)原代培养物中的表达,并对子宫内膜异位症患者的5-hmC水平进行定量。在妇科手术时采集血液、在位子宫内膜和子宫内膜异位组织。从无子宫内膜异位症(HESF-CONTROL)和有子宫内膜异位症(HESF-ENDO)的女性的在位子宫内膜中培养HESF,并进行体外蜕膜化。使用酶联免疫吸附测定法对血液和组织中的基因组DNA进行5-hmC绝对量的定量。与非子宫内膜异位症对照在位子宫内膜相比,子宫内膜异位症中TET1、TET2和TET3的表达降低。令人惊讶的是,异位子宫内膜中的5-hmC总量高于对照在位子宫内膜,而子宫内膜异位症女性血液中的基因组DNA所含5-hmC在统计学上显著低于无子宫内膜异位症的女性。在未蜕膜化的HESF-ENDO中,TET1、TET2和TET3的表达降低。在体外蜕膜化后,对照HESF中TET3的表达降低,而蜕膜化的HESF-ENDO中TET1、TET2或TET3的表达无统计学显著变化。这些结果表明,TET基因在异位子宫内膜和HESF-ENDO中下调,并首次表明TET基因在子宫内膜异位症中起作用。子宫内膜异位组织中较高的5-hmC总量表明这些组织中存在独特的表观遗传调控。